What is new for MDS with del(5q)?

During the7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to María Díez Campelo,...

What are novel strategies to treat low-risk MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Uwe...

Is there a place for immunotherapy in MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Shahram Kordasti,...

What are novel strategies to treat higher-risk MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Mikkael...

Will luspatercept become the new treatment standard after ESA failure in RS-positive LR-MDS patients with TD anemia?

Erythropoiesis-stimulating agents (ESAs) are the standard first-line treatment for...

The use of whole-genome sequencing as an alternative diagnostic tool for cytogenetic analysis in myeloid cancers

The use of whole-genome sequencing as an alternative diagnostic tool for cytogenetic...

Initiation of a phase II trial of lemzoparlimab combined with azacitidine to treat AML/MDS

On May 17, 2021, it was announced that the first patient has been dosed in China in a phase II trial...

Initiation of the first-in-human trial of FHD-286, a first-in-class dual inhibitor, to treat R/R AML

Patients with acute myeloid leukemia (AML) and myelodysplastic syndromes have very limited curative...

How should molecular profiling be used to guide MDS therapy?

During the Acute Leukemia Forum (ALF) 2021, the MDS Hub spoke to Rafael Bejar, UC San Diego, San Diego, US. We asked, How should molecular...

Germline mutations in patients with hematologic malignancies

Germline mutations in patients with neoplasms are more common than expected and have been found not only in children but also adults with...

Editorial theme | Immune dysregulation and genetic mutations associated with MDS pathogenesis

The pathogenesis of myelodysplastic syndromes (MDS) is heterogeneous, involving inflammation, cytokines,...

Eprenetapopt with azacitidine for TP53-mutant MDS/AML: Results from two ongoing clinical trials

Patients with TP53-mutant myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) experience...